Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
A2A Pharmaceuticals logo — company profile

A2A Pharmaceuticals

Founded 2016 10 employees Convertible Note Biotechnology, Health Care +2

General Information

Company Name A2A Pharmaceuticals
Founded Year 2016
Employees 10
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with A2A Pharmaceuticals. To contact A2A Pharmaceuticals, visit a2apharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About A2A Pharmaceuticals

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections.  Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

No funding data available for A2A Pharmaceuticals yet.

A2A Pharmaceuticals Alternatives & Competitors

A2A Pharmaceuticals vs
Circle Pharma, Inc.
Circle Pharma, Inc. United States

A New Paradigm For Macrocycle Drug Development

Series D
66 employees
Biotechnology, Health Care

FAQ About A2A Pharmaceuticals

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections.  Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These inte...
A2A Pharmaceuticals was founded in 2016.
A2A Pharmaceuticals operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical.
A2A Pharmaceuticals has approximately 10 employees.
Top alternatives and competitors to A2A Pharmaceuticals include Circle Pharma, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
A2A Pharmaceuticals and Circle Pharma, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for A2A Pharmaceuticals, https://bouncewatch.com/company/a2a-pharmaceuticals, updated 13 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes